Why does tamoxifen work better in some women? | University of Michigan Rogel Cancer Center
Medicina | Free Full-Text | Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis - The Lancet Oncology
Gels | Free Full-Text | Tamoxifen Citrate Containing Topical Nanoemulgel Prepared by Ultrasonication Technique: Formulation Design and In Vitro Evaluation
Tamoxifen: what you should and shouldn't avoid - OWise UK
CXCR4 Antagonist AMD3100 Reverses the Resistance to Tamoxifen in Breast Cancer via Inhibiting AKT Phosphorylation: Molecular Therapy - Oncolytics
Why women reject breast cancer preventing drug – new study
Cognitive Bias: The Downside of Shared Decision Making | JCO Clinical Cancer Informatics
Tamoxifen Helps Prevent Breast Cancer, but Women Reluctant to Take It
Why I'm taking tamoxifen to avoid breast cancer | MD Anderson Cancer Center
Making Choices
Tamoxifen to prevent breast cancer? - Website for Liz O'Riordan
mamo.cz - Tamoxifen class drugs reduce breast cancer rates by more than a third in women at high risk
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial - The Lancet
Combining Tamoxifen with Antidepressants: What You Need to Know
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - The Lancet
Why So Many of Us Quit Taking Tamoxifen | FORCE: Facing our Risk of Cancer Empowered Blog
5 tips for scientific survival from the Father of Tamoxifen
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models | npj Breast Cancer
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial - The Lancet
The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women - Value in Health Regional Issues
Breast cancer treatment without tamoxifen drug - non prescription
Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework | SpringerLink
Cancers | Free Full-Text | TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
